David Davidar Sells 25,000 Shares of Globus Medical (NYSE:GMED) Stock

Posted by George Bondi on Jun 9th, 2026

Globus Medical, Inc. (NYSE:GMED – Get Free Report) Director David Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Globus Medical Stock Performance

Shares of GMED traded up $4.30 during trading hours on Tuesday, hitting $82.60. 1,482,503 shares of the company were exchanged, compared to its average volume of 1,392,665. The company has a market cap of $11.21 billion, a PE ratio of 19.21, a PEG ratio of 1.65 and a beta of 0.95. The firm’s 50 day moving average is $86.08 and its 200-day moving average is $88.20. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GMED has been the subject of several research analyst reports. Wells Fargo & Company cut their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays boosted their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Check Out Our Latest Analysis on GMED

Hedge Funds Weigh In On Globus Medical

Several large investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC raised its holdings in Globus Medical by 2.3% in the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after acquiring an additional 151 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Globus Medical by 2.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock valued at $375,000 after acquiring an additional 170 shares in the last quarter. Parallel Advisors LLC raised its holdings in Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

About Globus Medical

(Get Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.